Infectivity of omicron BQ.1.1 comparison with other strains of SARS-Cov-2 in Japan
DOI:
https://doi.org/10.51094/jxiv.294Keywords:
SARS-CoV-2, effective reproduction number, BQ.1.1., omicron variant strain, vaccine coverage, waning in vaccine effectivenessAbstract
Abstract
Background: After decline of BA.5 sublineage of omicron variant strain of SARS-CoV-2, BQ.1.1. sublineage had been emerging.
Object: The object of this study was to estimate infectivity of BQ.1.1. sublineage controlling other factors that might affect BQ.1.1’s infectivity including vaccine effectiveness and waning, the mutated strain other than BQ.1.1, and countermeasuresBQ.1.1.
Method: The effective reproduction number(R(t)) was regressed on shares of BQ.1.1. as well as vaccine coverage, vaccine coverage with some delay, temperature, humidity, mobility, share of the other mutated strains, counter measures including Go To Travel Campaign and an Olympic Games. The study period was February, 2020 through the end of year 2022, as of January 31, 2023.
Results : We selected the specification with 90 days lag of waning. In this specification, Goto Travel Campaign and Olympic games were significantly negative and thus these event reduced infectivity. The estimated coefficient of BQ.1.1 sublineage of omicron variant strain was positive but insignificant.
Discussion: The obtained estimated results showed that BQ.1.1 may not have higher infectivity than BA.1, BA.2, BA.5 or other minor sublineage of omicron variant strains. It might be consistent with slower and gradually replacement from BA.5 to BQ.1.1.
Conflicts of Interest Disclosure
No author has any conflict of interest, financial or otherwise, to declare in relation to this study.Downloads *Displays the aggregated results up to the previous day.
References
European Centre for Disease Prevention and Control. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba.5. [accessed on January 22, 2023]
National Institute of Infectious Diseases. Updated Situation of COVID-19 Outbreak (July 13,2022) https://www.niid.go.jp/niid/ja/2019-ncov/11309-covid19-ab90th.html (in Japanese) [accessed on January 20, 2023]
Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. https://covid19.mhlw.go.jp/en/ [accessed on February 17, 2023]
Kurita J, Sugawara T, Ohkusa Y. Estimating Event Ban Effects on COVID-19 Outbreak in Japan. Journal of Health Science and Development 2021. 4: https://www.innovationinfo.org/articles/JHSD/JHSD-137.pdf
Tokyo metropolitan Government. Data of COVID-19 monitoring meeting in metropolitan Tokyo. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html (in Japanese) [accessed February 21,2023].
Prime Minister of Japan and His Cabinet. COVID-19 Vaccines. https://japan.kantei.go.jp/ongoingtopics/vaccine.html [accessed on February 17, 2023]
Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 2021:NEJMoa2114583.
Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021:NEJMoa2114114.
Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021.07.07.21260122; doi: https://doi.org/10.1101/2021.07.07.21260122
Downloads
Posted
Submitted: 2023-02-21 05:23:16 UTC
Published: 2023-02-24 06:50:44 UTC
License
Copyright (c) 2023
Junko Kurita
Tamie Sugawara
Yasushi Ohkusa
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.